Life Sciences Ontario Microbix summary from 11/22 Microbix is a profitable and growing, publicly-traded (TSX, OTCQX), awardwinning, Ontario-headquartered, world leader in the development and manufacture of specific biotechnology solutions for human health. The company has over 110 skilled employees based in Mississauga. It is currently ISO9001- and ISO13485 (Medical Device)-accredited, has a Pathogen and Toxin license issued by the Public Health Agency of Canada and a Medical Device Establish License (MDEL) from Health Canada. The company’s current 34,000ft2 campus comprises R&D, manufacturing, and testing facilities. The company makes a range of critical materials for the global diagnostics industry, notably infectious disease antigens for diagnostic immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable new test validation, or ensure the optimum accuracy of testing in clinical diagnostics laboratories. Microbix’s antigens enable the antibody tests of over 120 international diagnostics companies, while its QAPs are sold to globally to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. BARRIERS TO SUCCESS The health of Ontarians will be improved, and delivery costs reduced, if Ontario authorities maintain a Quality- and Value-based approach to strategic procurement, with meaningful focus on longer-term planning. Focus should also be on local procurement to support Ontarians and mitigate future supply chain issues. This approach will allow Ontario companies to plan for growth and more Ontarians to find high-quality employment. KEY WINS Microbix has more than doubled in size (footprint and staff) in the last 3 years. It provides Ontarians with rewarding, high-quality jobs. Microbix’s current QAPs portfolio is now available in over 30 countries. This encompasses over 200 separate products. Within these there are currently over 30 fully-regulated IVD medical devices that ensure testing accuracy for human diseases, including QAPs controls for all major variants of SARS-CoV-2 (COVID-19). Microbix has received support from FedDev Ontario to support this growth. In response to the COVID-19 pandemic, and with a grant from the Ontario Together Fund (MEDJCT), Microbix applied its expertise in sterile manufacturing, automation and quality management to produce a state-ofthe-art IVD viral transport medium (DxTMTM brand) to support COVID-19 (and other) testing in Ontario. To date, Microbix has provided over 2 million units of this vital, locally-made, product to the province. Microbix will continue helping Ontario and other provinces optimize infectiousdisease testing for respiratory viruses, sexually-transmitted infections, and other human pathogens of concern. LOOKING FORWARD COVID-19 has amply demonstrated the need for locally-derived capabilities to manage human infectious diseases. In future, other such diseases must be managed to support the health of Ontarians. These include respiratory infections (RSV, Flu, etc.), gastrointestinal pathogens, sexually-transmitted infections and antibiotic-resistant organisms. Microbix works in all of these areas, and more. In the coming years, Microbix will continue its profitable growth and will acquire further facilities and talented staff. The company intends to create a secure, Ontario-based global leadership position for assuring the best possible testing for human infectious diseases.
Market Data 
Markets 
AI
